Core Insights - The Institute for Functional Medicine (IFM) announced the formation of the 2026 Annual International Conference (AIC) Steering Committee, which will guide the strategic direction of the conference scheduled for May 27-30, 2026, in San Diego, CA, and via livestream [1][3] - The AIC Steering Committee comprises recognized experts in functional medicine from diverse geographic locations and practice scopes, contributing to the selection of clinical themes and educational presenters for the conference [2][3] - AIC 2026 will cover various topics, including advances in functional medicine research, clinical applications of artificial intelligence, personalized nutrition, genomics, the gut-brain axis, biorhythm and circadian health, women's health, and the integration of functional medicine into conventional healthcare [3][4] Company Overview - IFM has been a leading voice in functional medicine for over 30 years, focusing on transforming healthcare by addressing the unique physical, mental, and emotional needs of patients [6][9] - The organization supports the practice of functional medicine through ACCME-accredited education, certification programs, and advocacy for clinicians and patients globally [6][9] - IFM's FindaPractitioner.com is the largest functional medicine referral network worldwide, enhancing access to functional medicine practitioners [6] Certification Program - In 2026, IFM will launch the Functional Medicine Certification Program™, which aligns with industry accreditation standards to ensure the quality and relevance of functional medicine education [4][10] - The new certification program will offer two certifications: Functional Medicine Certified Professional (FMCP)™ and Functional Medicine Certified Professional – Medical (FMCP-M)™, guided by the National Commission for Certifying Agencies (NCCA) requirements [10]

Financial Data and Key Metrics Changes - The company reported consolidated revenues of $2.76 billion, an increase of 15.2% year-over-year, with organic revenue growth of 5.2% [15][18] - Adjusted earnings per share (EPS) grew by 11.5%, with reported EPS at $2.47 compared to $2.03 a year ago, and adjusted EPS at $2.62 versus $2.35 [17][18] - Cash from operations increased by 67.1% year-over-year to $858 million [18] Business Line Data and Key Metrics Changes - Revenues for Diagnostic Information Services rose by 15.7%, driven by acquisitions and organic growth in physician and hospital channels [15] - The physician channel experienced approximately 20% revenue growth, primarily from acquisitions and high single-digit organic growth [8] - Hospital channel revenues grew in low single digits, supported by collaborative lab solutions [9] Market Data and Key Metrics Changes - The company saw a total volume increase of 16.3% in requisitions, with organic volume up 2.1% [15] - Revenue per requisition decreased by 0.4% year-over-year, but on an organic basis, it increased by 3.3% due to more tests per requisition [16] Company Strategy and Development Direction - The company aims to drive growth through innovative solutions tailored to the evolving needs of core clinical customers and expanding into consumer, life sciences, and data analytics [5][6] - Focus areas include advanced diagnostics in cardiometabolic, autoimmune, brain health, oncology, and women's health [7] - The company is investing in automation and AI technologies to enhance operational efficiency and customer experience [12][13] Management's Comments on Operating Environment and Future Outlook - Management raised the full-year 2025 guidance based on strong second-quarter performance and continued utilization trends [5][20] - The company anticipates organic revenue growth of approximately 3.5% to 4% for the full year, alongside contributions from acquisitions [18][19] - Management expressed confidence in absorbing the impact of tariffs and other economic factors within their guidance [71][74] Other Important Information - The company is focused on expanding access to its consumer channel, achieving significant growth in online offerings [10] - The integration of the LifeLabs acquisition is progressing well, contributing approximately 8% to the 10% growth from M&A in the quarter [79][82] Q&A Session Summary Question: Impact of uninsured individuals due to recent legislation - Management estimates a minimal impact on volume in 2026, projecting a 30 to 40 basis point effect from potential uninsured individuals [25][29] Question: Modernization investments and margin expectations - The company expects to incur approximately $0.20 in modernization expenses, with continued margin expansion anticipated for the full year [37][39] Question: Functional medicine as a growth driver - Management indicated that functional medicine is a significant growth area, with expectations for double-digit growth moving forward [95][96] Question: Haystack MRD test progress - Positive feedback from oncologists has been received, with expectations for continued growth in the Haystack MRD business [107] Question: Wage increases and labor trends - Wage inflation is expected to remain in the 3% to 4% range, with improved employee retention aiding productivity [91][92]